Click on the links below to preview selected pages from this course.
- Background and Overview of Preeclampsia
- Background and Overview
- Which of the following statements is NOT true in describing preeclampsia (PE)?
- Preeclampsia (PE) affects 5-10% of pregnant women and typically occurs after 20 weeks' gestation.
- Classification and Characteristics of Preeclampsia
- Classification and Characteristics of Preeclampsia (PE)
- HELLP Syndrome
- Which of the following can be defined as the presence of hypertension (blood pressure ≥ 140/90) on two occasions at least six hours apart but wi...
- What condition NOT attributable to any other disorder is associated with eclampsia?
- Which statement is TRUE regarding the HELLP syndrome?
- Risk Factors for Preeclampsia
- Risk Factors for Preeclampsia (PE)
- Which of the following are considered risk factors for PE?
- Pathophysiology of Preeclampsia
- Treatment and Prevention
- Treatment and Management of Preeclampsia (PE)
- Treatment and Management of PE, continued
- Treatment and Prevention (Aspirin Usage)
- Postpartum PE
- True or false? The only cure for PE is the delivery of the baby.
- Which statements are true regarding the use of aspirin to prevent PE?
- Current Laboratory Testing Used for PE Workup
- Emerging Biomarkers for Preeclampsia
- Emerging Biomarkers to Identify Risk for Preeclampsia (PE)
- Angiogenesis and Angiogenic Biomarkers
- Table I: Circulating Levels of Angiogenic Biomarkers in Preeclampsia (PE)
- Table II: Circulating Levels of Other Potential Biomarkers in Preeclampsia (PE).
- Laboratory Methods for Quantitation of Biomarkers Used for Determining Risk of PE
- New FDA-approved Biomarker Test System: The Thermo Scientific PlGF and sFlt-1 Test System.
- Angiogenesis is the physiological process through which new blood vessels form from pre-existing vessels.
- What statements are TRUE concerning angiogenesis and angiogenic biomarkers?
- PIGF acts as a vasodilator, increasing the diameter of existing arteries, and its serum levels have been found to be significantly lower in mild and s...
- Choose the correct answer regards the circulating levels of sFlt-1, sEng, and the sFlt-1/PIGF ratio in pregnant women with preeclampsia (PE).
- Which potential preeclampsia (PE) biomarker that is decreased in PE can be described as a glycoprotein, which is derived from the trophoblast cells an...
- Which potential PE biomarker is a cell surface molecule expressed by platelets and endothelial cells, and circulating levels are increased in PE?
- Which statements are true regards the Thermo Fisher Scientific Test System used to aid in the prognosis of PE with severe features in pregnant women?
- Summary and Conclusions
Level of instruction: Intermediate
Intended Audience: Medical laboratory scientists, medical technologists, and technicians. This course is also appropriate for medical laboratory science students and pathology residents.
Author information: David Moffa, PhD, has over 30 years of experience in the health care industry as an executive manager, clinical laboratory director, and medical laboratory scientist. He is currently a technical consultant for Kentmere Healthcare, Wilmington, DE, and until his retirement, was the Regional Director for LabCorp, Inc. He holds a PhD in medical biochemistry from the School of Medicine, West Virginia University.
Reviewer information: Prior to her retirement in 2012, Jenny Camele was employed by Laboratory Corporation of America as the manager of customer service operations for the Fairmont West Virginia Region and a Quality Assurance committee member. She holds a Bachelor of Science degree in Medical Technology from West Virginia University.